We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
- Authors
Reardon, David A; Egorin, Merrill J; Quinn, Jennifer A; Rich, Jeremy N; Gururangan, Sridharan; Vredenburgh, James J; Desjardins, Annick; Sathornsumetee, Sith; Provenzale, James M; Herndon, James E, 2nd; Dowell, Jeannette M; Badruddoja, Michael A; McLendon, Roger E; Lagattuta, Theodore F; Kicielinski, Kimberly P; Dresemann, Gregor; Sampson, John H; Friedman, Allan H; Salvado, August J; Friedman, Henry S
- Abstract
We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme (GBM).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 36, p9359
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.03.2185